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IMMUNOPROPHYLAXIS OF STAPHYLOCOCCUS AUREUS MASTITIS IN DIARY COWS
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Mastitis in cows represents one of the most actual problems in
intensive dairy production. The prevention of pathogen penetration in
the udder, its colonization and reproduction impose the constant need
for regular milk check-ups, and preventive and therapeutic measures.
Staphylococcus aureus causes subclinical and clinical mastitis, which
when in the acute form can originate difficult and malignant udder
infections with granulomatous and necrotic changes. Chronic forms of
Staphylococcal mastitis most often pass as subclinical cases. An
efficient commercial vaccine has not been introduced yet, though the
application of autochthonous vaccines in the prevention of mastitis can
give satisfactory results.
In this study we have developed and applied an autochthonous
vaccine prepared from S. aureus isolated from milk samples taken from
an experimental farm, as well as from the referent capsular strain S.
aureus. The vaccine was applied to experimental dairy cattle twice
before calving in a dose of 5 mL. It consisted of inactivated bacterial S.
aureus JR3 cells in a quantity of 1x1010 cfu/mL and 5 mg SM capsule of
the strain S. aureus 2286. This vaccination of dairy cows has resulted in
a significant decrease of subclinical and clinical manifested mastitis in
the treated group, when compared to the vaccinated group of
experimental animals.
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INTRODUCTION
Mastitis in dairy cows is one of the most common problems in intensive
diary production. It is the cause of striking economic losses, which in the last
decade ranged from 12 to 80%. The applied approaches to mastitis therapy have
not given satisfactory results up to now, thus the problem of mastitis therapy is still
present and actual. Local and parentheral antibiotic therapy, as well as adequate
zooprophylactic and hygienic measures, proper milking and nutrition can give
satisfactory results and decrease the incidence of mastitis. However, the problem
is still present in intensive diary production, so new solutions with a modern
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approach have to be developed. Such solutions are reflected in the development
of immunoprophylaxis and immunotherapy protocols.
Staphylococcus aureus udder infections in cows represent one of the major
problems in intensive diary production. Of the total number of mastitis cases in
dairy cows, those caused by S. aureus are represented in the range from 19% to
40% of all cases.
Published papers about vaccination of ruminants against causative mastitis
agents describe limited positive results. In the '30ties it has been described that
subcutaneous inoculation with viable S. aureus in sheep results in an increased
resistance to experimentally induced mastitis (Munch-Peterson, 1938). During the
'70ties vaccination against mastitis inducing antigens was based on polyvalent
vaccines, which contained immunogenic staphylococcus, streptococcus and
coliform bacterial strains, as well as exotoxins and endotoxins. Recent vaccines
against Staphylococcus aureus induced mastitis contain inactivated S. aureus
cells (Giraudo, 1997).
A number of papers indicate that in order to develop an inactivated S. aureus
vaccine of a better quality alpha and beta toxoids, as well as capsular fragments of
this pathogen have to be added (Calzolari, 1997; Watson, 1996; Leitner, 2003).
Guidry (1994), Opdbeeck (1988) and Lee (2005) have described the preparation
of the vaccine containing capsular antigens. Nordhaug (1994) states, as a new
possibility the addition of protein A and fibronectin-binding protein as antigens in
the stimulation of the active immune response. A completely new approach in the
immunization of the udder was given by O'Brien (2001) who incorporeted the S.
aureus lysate into biodegradable particles which have the function to stimulate
antibody production and opsonization.
MATERIAL AND METHODS
Isolation and identification of S. Aureus vaccinal strains
Parallel to our outochtonous strains (JR1, JR2, JR3 and JR4) the referent
capsular strain of S. aureus 2286 was studied and included in the vaccine
preparation. This pathogen does not require specific growth media. It grows well
on blood agar containing 5 – 10% blood and forms regular, round, slightly convex
colonies (Quinn, 2002)
Vaccine preparation
The vaccine was prepared from the autochtonous strain JR3 which
displayed the most typical biochemical characteristics of S. aureus and the
referent capsulated strain 2286.
Vaccine constituent A.
A total of 5L of Brain-Heart infusion was seeded with the isolated strain S.
aureus JR3. The so inoculated medium was incubated at 37oC for 24 h. After this
incubation period 0.4% vol/vol formalin was added and incubation continued for
further 24h. After the microorganism was inactivated by formalin the culture was
centrifuged at 7000 rpm at 4oC for 20 min. The success of the inactivation process
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was checked out by repeating the incubation of a sample on blood agar. Lack of
bacterial growth indicated that inactivation was successful.
After centrifugation the supernatant was discarded and the sediment
resuspended in 0.9% NaCl at pH 7.0. The resuspended sediment represents the
first constituent (A) of the vaccine.
Vaccine constituent B
The next step was the preparation of the referent capsular strain S. aureus
2286 which was seeded in 5L of Brain-Heart infusion, as well. The so inoculated
medium was incubated at 37oC for 24 h and thereafter centrifuged at 7000 rpm at
4oC for 20 min. The sediment was resuspended in saline and sterilized in an
autoclave at 121oC, thus the referent strain S. aureus 2286 was inactivated.
Subsequently, the sample was centrifuged under the same conditions as strain
JR3. The obtained supernatant represents the second constituent (B) of the
vaccine, consisting of capsules of the strain S. aureus 2286. In the supernatant
0.4% vol/vol formalin and 0.001% wt/vol of conservant timerasol were added.
The dose of the vaccine was 5 mL/cow, containing inactivated bacterial S.
aureus JR3 cells in a quantity of 1x1010 cfu/mL (constituent A) and 5 mg SM
capsule of strain S. aureus 2286 (constituent B).
By preparing the vaccine in the described manner a total of 135 doses (5 mL
each) was obtained.
Vaccine sterility and toxicity tests
To test for sterility the vaccine was seeded into 2 test tubes containing serum
broth, 2 test tubes containing nutritious broth, Jansen's media with added starch
and Jansen media with glucose added, nutritious oblique agar and blood agar. In
none of the listed media aerobic or anaerobic bacterial growth was recorded. This
proved that the vaccine was sterile.
Toxicity was tested for on a total of 10 white mice, 2 guinea pigs, 4 sheep and
5 pregnant cows. The vaccine in a dose of 5mL was applied in two different ways
i.e. there were two groups of 5 mice each. To one group the vaccine was applied
intraperitoneally, and to the other group the route of application was
subcutaneous. Mice to which the vaccine was applied intraperitoneally passed
the biological test by not displaying any clinical signs. On post mortem
examination there were no evident changes on the application site nor on
parenchymatous organs. Mice to which the vaccine was applied subcutaneously
behaved similarly, but showed on the application site small nodules.
Tests on guinea pigs and sheep did not indicate vaccine toxicity. The
vaccine in a dose of 5 mL was applied subcutaneously in the neck region to
pregnant cows, two months prior to calving. After vaccination there were no
obvious changes in health status, feed intake, rumination or body temperature.
On the application site a nodule the size of a nut was easy to palpate for a period of
10 - 20 days, after which it was reabsorbed. Thus, it was decided to administer the
vaccine in two shots, 2.5 mL each, one on each side of the neck in the brachial
region.
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Cytology tests
The number of milk somatic cells was studied under a light microscope. Milk
samples for cytology tests were prepared in the following fashion: on a
microscope glass slide 0.01 mL of milk was smeared over a surface of 1 cm2. To
achieve this a piece of thin white cardboard marked with a 1 cm x 1 cm square was
placed under the glass slide. After drying-up the sample at room temperature for
24h, fats from the smear were removed with xylol, dried up and fixed in ethanol for
5 minutes. Thereafter the samples were dried and dyed with the previously
prepared dye.
The number of somatic cells was determined by a formula that defines the
microscope factor (MF) and the average cell count in 5 field views:
MF = 100/r2 x n
MF - microscope factor, r - diameter of the eye field circle,  - 3.14, x - number of
field viewings, n - average number of leucocytes counted.
Immune tests
Tests for S. aureus antibodies in milk samples were carried out by
commercial ELISA test (manufactured by VMRD, USA) in accordance to the
manufacturer’s instructions. Readings were performed at 620 nm.
Experiment
In the experiment a total of 42 pregnant Holstein-Friesian cows, 4-5 years of
age was included. Twenty-one cows were vaccinated two months before calving
(start of dry period) and revaccinated one month prior to the expected date of
delivery. The vaccine was administered subcutaneously in the neck region in a
dose of 5 mL. To the control group a placebo vaccine, consisting of 5 mL sterile
saline was applied in the neck region, as well.
In order to determine the presence of S. aureus, milk samples were taken
from all experimental cows before vaccination and after calving thereof in monthly
intervals until first signs of clinical or subclinical mastitis were evident. The overall
duration of the trial was 8 months. Samples were tested for specific antibodies,
cell count and bacteria.
RESULTS
In an experimental dairy farm, which over a long period of time showed a
high incidence of clinical and subclinical mastitis, the described protocol showed
the following results:
Microbiological tests of milk samples from vaccinated and control dairy
cows suffering from clinical or subclinical mastitis caused by S. aureus
Microbiological tests were carried out on milk samples from both groups
starting prior to the dry term, which coincides with the first vaccination and thereof
in regular monthly intervals after calving until first signs of mastitis in the
experimental group were evident (Table 1).
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21 7.00 33.30 3.00 14.20 3.00 14.20 0.00 0.00
Control
group
21 4.00 19.00 8.00 38.00 5.00 23.00 3.00 14.20
n = Number of diary cows
At the beginning of the trial S. aureus was identified in n = 7 (33.30%) milk
samples from vaccinated cows and in n = 4 (19.00%) milk samples in the control
group. After 8 months, at the end of the trial S. aureus was identified in n = 3
(14.20%) milk samples from vaccinated cows. At the same time a total of n = 8
(38.00%) milk samples from the unvaccinated group tested positive for S. aureus.
Subclinical mastitis was present in n = 5 (23.00%) control cows, and in n = 3
(14.20%) vaccinated experimental cows. Clinical forms of mastitis were absent in
the vaccinated group, while in the control group three cases (14.20%) were
confermed by microbiological testing.
Somatic cell count and antibody levels
Somatic cell count (SCC) in milk samples was carried out by counting the
cells under light microscope. The level of specific S. aureus antibodies was
performed by standard ELISA test (Staphylococcus Aureus Antibody Test Kit,
VMRD). In order to provide a better insight into the obtained results the statistical
measure "indexed number" was applied. This index is used in order to show the
changes of a variable (or a group of variables) over a given time period,
geographical location or some other relevant parameter. By calculating the
indexed series (starting with 100% or 0%) over a time period, the change, given as
a percentage of the starting value, can be expressed referent to the starting point.
Maximal values for antibody levels in the control group at the start of the dry
period were in the range from 0.606 OD (optical density) to 1.410 OD. At the same
time the minimal values, within the same group, ranged from 0.092 OD to 0.102
OD. Within the vaccinated group maximal antibody values were from 0.957 OD to
1.534 OD, and the minimal from 0.375 OD to 0.512 OD.
The antibody level value in dairy calves before the dry period was 0.865 ±
0.165 OD in the control group and 0.974 ± 0.148 OD in the vaccinated group.
After calving the values were 0.842 ± 0.148 and 1.162 ± 0.165, respectively. In the
third month after calving the level of antibodies in the control group decreased to
0.299 ± 0.165 OD and did not change significantly until the end of the experiment.
Maximal values for milk SCC in the control group during the period of the
trial ranged from 912.000/ mL to 2.048.000/ mL. In the same period the minimal
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reported values ranged from 27.200/ mL to 78.000/ mL. During the same period
the highest reported SCC values in the vaccinated group were within the range
from 1.145.600/ mL to 2.240.000/ mL and the minimal from 21.333/ mL to
97.600/ mL.
At the start of the trial the average SCC in 1 mL milk samples was
1.021.550 ± 248.429/ mL in the control group and 776.350 ± 297.312/ mL in the
experimental group.
After calving the average SCC was 799.500 ± 248.429/ mL in the control
group and 853.600 ± 297.312/ mL in the experimental group of diary cows.
Three months after delivery the SCC in both groups was in the range from
300.000/mL to 600.000/mL.
If the obtained values are indexed it becomes obvious that antibody levels
from the starting value of 100% decreased to 33% and 54% in the control and
vaccinated group, respectively. At the same time, SCC from the starting value of
100% decreased to 47% and 80% in the control and vaccinated group,
respectively (Figure 1).
It is clear that the averages, minimal and maximal values for antibody
concentrations in the vaccinated group are higher compared to the control group
throughout the trial. In both groups there is a steady increase in antibody levels
during the first two months, thereof the values decrease.
The indexed mean values of antibody levels in milk samples from
vaccinated diary cows are higher throughout the duration of the trial (Figure 2).
The diagram clearly shows a steady increase of antibody levels in milk samples
during the first two months, followed by a gradual decrease until the third month of
the trial when it reaches a steady state. The indexed antibody levels in the control
group were 86% and 22% of the initial values in the control and vaccinated group,
respectively.
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Figure 1. Level of antibodies (OD)
DISCUSSION
Stojanovic et al. (2001) still consider mastitis to be one of the causes of
greatest economic losses in diary farms. It is estimated that at least 40% of cows
are infected by mastitis causing agents, but only 2-3% show signs of clinical forms
of mastitis. Subclinical forms are often caused by S. agalactiae, Streptococcus
spp., S. aureus and Staphylococcus spp. If only identified cases of subclinical
mastitis caused by S. agalactie and S. aureus were observed a total from 16%
(Nordhaug 1994, Edinger 2000) to 19% of observed dairy cows (Giraudo 1997)
was affected. Our results have shown a higher incidence (33.30%) of subclinical
mastitis in diary cows.
Nordhaug (1994) described the incidence of subclinical mastitis caused by
S. aureus to be present in 16% unvaccinated and 8.6% vaccinated dairy cows.
Leitner et al. (2003) reported an extremely low incidence of cases of S. aureus
subclinical mastitis, i.e. in 2.7% controls and among 1.3% vaccinated dairy cows.
A much higher frequency of subclinical mastitis was reported by a number of
authors. Watson (1996) reported 43% and 35.4% in control and vaccinated dairy
cows, respectively. Similar results are published by Giraudo (1997) who identified
a total of 40% of S. aureus subclinical mastitis in a herd of unvaccinated dairy
cows and 15% among those that underwent prior vaccination.
Our results are close to those reported by Watson (1996) and Giraudo
(1997). The experiment we have carried out has shown that a total of 23% of
unvaccinated and 14.2% vaccinated dairy cows suffered from subclinical mastitis
at the end of the experiment, relative to the 33% suffering at the very start of the
research.
Based upon the obtained experimental results it can be concluded that the
incidence of subclinical S. aureus mastitis could be lowered even more if a second
vaccination was introduced four months after revaccination when antibody levels
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Figure 2. Indexed antibody values (%)
in the milk are at their lowest. By introducing this additional revaccination the
existing decrease in antibody concentration could be avoided.
Edinger (2000) has described a very low incidence of clinical forms of S.
aureus mastitis, which in the control group was present in 3.8% cases and in 2.4%
vaccinated dairy cows. Giraudo (1997) has established 12.5% clinical mastitis
cases among the control cows and 2.5% cases within the studied population of
vaccinated diary cows. An extremely high incidence of clinically manifest mastitis
in diary cows (34.5% in the control group and 16.3% in the vaccinated group) was
described by Watson (1996) and Smith (2006). Nordhaug (1994) has established
the presence of clinical mastitis in 6% control diary cows, while no cases were
registered among the vaccinated animals.
Our results are close to those published by Nordhaug (1994), as among the
vaccinated animals there were no cases of clinical S. aureus mastitis. At the same
time in the unvaccinated control group a total of 14.2% displayed clear signs of
mastitis. These results point out to the possibility of reducing the incidence of
clinical forms of mastitis by immunoprophylaxis.
During involution of the mammary gland SCC increases up to
1.000.000/mL. However, before delivery this number decreases to physiological
values (Seiff, 1932; Schalm, 1971; Nickerson, 1989). Our results have shown that
the number of milk somatic cells at the beginning of the dry period was close to
the published data i.e. 1.000.000/mL and 800.000/ml in the control and treated
group, respectively. According to Frerking (1961) at the beginning of lactation the
SCC can increase up to 2.500.000/mL. In our trial, at the beginning of the
experiment, the SCC was close to 800.000/mL in both groups. The obtained
results are close to the findings of Giraudo (1997), Hoedmaker (1999), Edinger
(2000).
When the number of somatic cells was indexed a minor decrease in SCC
was determined within the experimental group when compared to the vaccinated
group. When compared to the starting values the SCC fell within the control group
down to 47%, and to 80% in the vaccinated group. The higher count of milk
somatic cells in the vaccinated group throughout the trial period can be
accounted to the activation of cellular immunity as a response to the applied
vaccine.
According to Stojic (2000) the concentration of IgG antibodies in milk is low
(1-2 mg/mL) and primarily depends on vascular permeability of the blood/milk
barrier. When during inflammation the integrity of the barrier is altered, the
concentration of antibodies in milk increases to 50 - 80 mg/mL. It is known that
antibody levels in the dry period and in the colostrum are high, which is in
agreement to our results. The average antibody concentration in the control and
in the vaccinated group during the dry period was 0.851 OD and 0.992 OD,
respectively. Colostrum had an average antibody concentration in the control
samples of 0.838 OD, while colostrum from the vaccinated group had an average
antibody concentration which was much higher i.e. 1.187 OD.
High antibody levels in the vaccinated group at the start of the dry period are
considered to be induced by the experimental vaccine. A high antibody titre in the
colostrum of vaccinated cows has been described by Opdebeeck (1985), as well.
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After indexing the antibody levels a decrease in the values in the control group to
33% and in the vaccinated group to 54% from the starting value is evident. A
significantly higher antibody concentration in the vaccinated group throughout
the trial was determined by Opdebeeck (1985), Loeffer (1987), Nordhaug (1994),
O' Brien (2000) and others.
Based upon our results it can be concluded that among diary cows that
have been vaccinated twice during pregnancy with the tested vaccine, the
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IMUNOPROFILAKSA MASTITISA KRAVA IZAZVANOG SA
STAPHYLOCOCCUS AUREUS
VAKANJAC SLOBODANKA, PAVLOVI] M, PAVLOVI] V i OBRENOVI] SONJA
SADR@AJ
Mastitisi krava predstavljaju jedan od najaktuelnijih problema u intenzivnoj
proizvodnji mleka. Spre~avanje prodora patogenog uzro~nika u mle~nu `lezdu,
njegovo naseljavanje i razmno`avanje, name}u stalnu potrebu za redovnom kon-
trolom mleka, kao i preduzimanje preventivnih i terapijskih mera. Staphylococcus
aureus izaziva subklini~ke i klini~ke forme mastitisa, koje mogu u akutnoj formi da
izazovu te{ke, maligne mastitise u vidu granulomatoznih i nekroti~nih promena.
Hroni~ne forme stafilokoknog mastitisa uglavnom ~esto prolaze kao subklini~ki
oblici obolenja mle~ne `lezde Jo{ uvek nije prona|ena komercijalna efikasna
vakcina protiv mastitisa izazvanog S. aureus-om, ali primena autohtonih vakcina u
preveniranju mastitisa mo`e dati zadovoljavaju}e rezultate. Koristili smo autoh-
tonu vakcinu koju smo pripremili od S. aureus-a izolovanog iz mleka uzetog sa
ogledne farme i referentnog kapsularnog soja S. aureus. Vakcina je dvokratno
aplikovana oglednim kravama dva meseca pred telenje u dozi od 5 ml, a sastojala
se od inaktivisanih bakterijskih }elija S. aureus JR3 u koli~ini od 1x1010 cfu/ml i 5
mg SM kapsule soja S. aureus 2286. Ovaj na~in vakcinisanja krava protiv mastitisa
izazvanog Staphylococcus aureus-om doveo je do smanjenja subklini~kih i
klini~kih mastitisa u zna~ajno manjem procentu u odnosu na kontrolnu grupu
krava.
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